Fortress Biotech (NASDAQ:FBIO – Get Free Report) announced its quarterly earnings results on Friday. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.04, FiscalAI reports. Fortress Biotech had a return on equity of 83.47% and a net margin of 163.32%. The business had revenue of $19.16 million during the quarter, compared to the consensus estimate of $21.57 million.
Fortress Biotech Price Performance
Shares of Fortress Biotech stock traded down $0.11 during midday trading on Friday, hitting $1.88. 310,600 shares of the company traded hands, compared to its average volume of 208,983. Fortress Biotech has a 12 month low of $1.75 and a 12 month high of $4.53. The stock has a market cap of $62.70 million, a price-to-earnings ratio of 0.71 and a beta of 1.27. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.83 and a current ratio of 3.96. The firm’s fifty day moving average price is $2.14 and its 200-day moving average price is $2.72.
Analyst Ratings Changes
FBIO has been the subject of a number of analyst reports. Weiss Ratings downgraded Fortress Biotech from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, October 23rd. Wall Street Zen cut shares of Fortress Biotech from a “strong-buy” rating to a “hold” rating in a research report on Saturday, August 15th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Fortress Biotech presently has a consensus rating of “Hold” and a consensus target price of $17.00.
Get Our Latest Stock Report on Fortress Biotech
About Fortress Biotech
Fortress Biotech, Inc. is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiaries and affiliated companies. Its approach includes advancing drug candidates, acquiring or licensing development and commercialization rights, and building companies around selected products and programs. The company’s activities span areas including oncology, dermatology, rare diseases and immunology. Its portfolio has included marketed dermatology medicines such as Qbrexza, Amzeeq and Zilxi, as well as investigational therapies at various stages of development.
Read More
- Five stocks we like better than Fortress Biotech
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
- Why Equinix and Digital Realty Benefit From Data Center Zoning Battles
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
